Zobrazeno 1 - 10
of 763
pro vyhledávání: ''
Autor:
Andreas Schneeweiss, Wolfgang Wick, Georg Martin Haag, Joachim Wiskemann, Jana Müller, Karen Steindorf, Markus Weiler
Publikováno v:
British Journal of Cancer
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common, unpleasant and usually long-lasting side effect of neurotoxic chemotherapeutic agents. This study aimed to investigate the preventive potential of sensorimotor- (SMT) and resis
Autor:
Stephane Ferretti, Sébastien Jeay, Ensar Halilovic, Claire Fabre, Laurence Van Bree, Christophe Meille, Jens Wuerthner, Florence Hourcade-Potelleret, Sebastian Bauer, Reinhard Dummer, Philippe A. Cassier, Astrid Jullion, George D. Demetri, Nelson Guerreiro, Daniel Shao-Weng Tan
Publikováno v:
British Journal of Cancer
Background CGM097 inhibits the p53-HDM2 interaction leading to downstream p53 activation. Preclinical in vivo studies support clinical exploration while providing preliminary evidence for dosing regimens. This first-in-human phase I study aimed at as
Publikováno v:
Br J Cancer
Background Microwave ablation (MWA) is an effective minimally invasive technique for lung tumours. We aim to evaluate its role for pulmonary oligorecurrence after radical surgery of non-small-cell lung cancer (NSCLC). Methods From June 2012 to Jan 20
Autor:
David Sefrioui, Ludivine Beaussire, André Gillibert, France Blanchard, Emmanuel Toure, Céline Bazille, Anne Perdrix, Frédéric Ziegler, Alice Gangloff, Mélanie Hassine, Caroline Elie, Anne-Laure Bignon, Aurélie Parzy, Philippe Gomez, Caroline Thill, Florian Clatot, Jean-Christophe Sabourin, Thierry Frebourg, Jacques Benichou, Karine Bouhier-Leporrier, Marie-Pierre Gallais, Nasrin Sarafan-Vasseur, Pierre Michel, Frédéric Di Fiore
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2021, ⟨10.1038/s41416-021-01431-9⟩
Br J Cancer
British Journal of Cancer, Cancer Research UK, 2021, ⟨10.1038/s41416-021-01431-9⟩
Br J Cancer
BACKGROUND: We previously reported that CEA kinetics are a marker of progressive disease (PD) in metastatic colorectal cancer (mCRC). This study was specifically designed to confirm CEA kinetics for predicting PD and to evaluate CA19-9, cell-free DNA
Autor:
Hansjörg Baurecht, Sebastian E. Baumeister, Michael F. Leitzmann, Anja M. Sedlmeier, Andreas Weber, Carmen Jochem, Sebastian Haferkamp
Publikováno v:
British Journal of Cancer
Background Physical activity has been positively related to malignant melanoma. However, that association may be confounded by ultraviolet radiation (UV), a variable closely related to both outdoor physical activity and malignant melanoma. We examine
Autor:
Rasima Cehic, Steven Attia, Irene Helenowski, Susan Abbinanti, Angela C. Hirbe, Peter Oppelt, Mark Agulnik, Varun Monga, Brian A. Van Tine, Nisha Mohindra, Brian C Schulte, John A. Charlson, Mohammed M. Milhem, Steven I. Robinson, Scott H. Okuno
Publikováno v:
Br J Cancer
Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with sarcoma. Meth
Autor:
John Pollard, Ruth Plummer, Thomas Jeff Evans, Mark R. Middleton, Martin H. Falk, Geoffrey I. Shapiro, Ivan Diaz-Padilla, Bart S. Hendriks, Emma Dean
Publikováno v:
British Journal of Cancer
Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib + gemcitabine ± cisplatin
Publikováno v:
Br J Cancer
Background We sought to estimate the annual risk and 25-year cumulative risk of contralateral breast cancer among women with stage 0-III unilateral breast cancer. Methods We identified 812,851 women with unilateral breast cancer diagnosed between 199
Autor:
Haifeng Qin, Gongyan Chen, Donghua Lou, Jianhua Shi, Kai Li, Qiming Wang, Baohui Han, Lin Wu, Jie Wang, Shanchun Wang, Ying Cheng, Ying Liu, Hao Yu, Xiaoling Li, Jianxing He
Publikováno v:
Br J Cancer
BACKGROUND: This study aimed to evaluate the efficacy and safety of anlotinib as a third-line and subsequent treatment for patients with small cell lung cancer (SCLC). METHODS: We conducted this Phase 2 trial at 11 institutions in China. Patients wit
Autor:
Michele Ciccarelli, Nicolò Gennaro, Alexia Bertuzzi, Marco Alloisio, Armando Santoro, Umberto Cariboni, Laura Giordano, Andrea Dipasquale, Vittorio Quagliuolo, Andrea Marrari
Publikováno v:
British Journal of Cancer
Background The impact of active cancer in COVID-19 patients is poorly defined; however, most studies showed a poorer outcome in cancer patients compared to the general population. Methods We analysed clinical data from 557 consecutive COVID-19 patien